| Chibong Alex Yu, DO, MPH | |
|
100 S Raymond Ave, Alhambra, CA 91801-3166 | |
| (951) 929-6260 | |
| (951) 765-2855 |
| Full Name | Chibong Alex Yu |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 12 Years |
| Location | 100 S Raymond Ave, Alhambra, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043573694 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 20A14168 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Bernardine Medical Center | San bernardino, CA | Hospital |
| San Gabriel Valley Medical Center | San gabriel, CA | Hospital |
| Community Hospital Of San Bernardino | San bernardino, CA | Hospital |
| Alhambra Hospital Medical Center | Alhambra, CA | Hospital |
| Garfield Medical Center | Monterey park, CA | Hospital |
| Entity Name | Providence Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285890624 PECOS PAC ID: 8921993205 Enrollment ID: O20040216001346 |
News Archive
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency, also known as Wolman disease.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).
Innate Immune, Inc., a privately held biotechnology company, today announced that it has granted to Cephalon Australia Pty Ltd an exclusive license to patents for the development of its antibodies for the treatment of asthma and systemic lupus erythematosis (SLE).
Scientists today described key advances toward practical uses of a new genre of tiny, biocompatible electronic devices that could be implanted into the body to relieve pain or battle infection for a specific period of time, and then dissolve harmlessly.
A unique Network studying the health and wellbeing of older people is bringing together health, social science and mathematics experts in a revolutionary project which will help shape the long-term provision of health and social care services across the UK and ultimately benefit older people.
› Verified 9 days ago
| Entity Name | Inpatient Specialists Of California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952792475 PECOS PAC ID: 3476864448 Enrollment ID: O20150617000915 |
News Archive
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency, also known as Wolman disease.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).
Innate Immune, Inc., a privately held biotechnology company, today announced that it has granted to Cephalon Australia Pty Ltd an exclusive license to patents for the development of its antibodies for the treatment of asthma and systemic lupus erythematosis (SLE).
Scientists today described key advances toward practical uses of a new genre of tiny, biocompatible electronic devices that could be implanted into the body to relieve pain or battle infection for a specific period of time, and then dissolve harmlessly.
A unique Network studying the health and wellbeing of older people is bringing together health, social science and mathematics experts in a revolutionary project which will help shape the long-term provision of health and social care services across the UK and ultimately benefit older people.
› Verified 9 days ago
| Entity Name | Access Telecare Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013303080 PECOS PAC ID: 7810204831 Enrollment ID: O20190531002079 |
News Archive
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency, also known as Wolman disease.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).
Innate Immune, Inc., a privately held biotechnology company, today announced that it has granted to Cephalon Australia Pty Ltd an exclusive license to patents for the development of its antibodies for the treatment of asthma and systemic lupus erythematosis (SLE).
Scientists today described key advances toward practical uses of a new genre of tiny, biocompatible electronic devices that could be implanted into the body to relieve pain or battle infection for a specific period of time, and then dissolve harmlessly.
A unique Network studying the health and wellbeing of older people is bringing together health, social science and mathematics experts in a revolutionary project which will help shape the long-term provision of health and social care services across the UK and ultimately benefit older people.
› Verified 9 days ago
| Entity Name | Access Telecare California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861959959 PECOS PAC ID: 8325373525 Enrollment ID: O20190710002532 |
News Archive
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency, also known as Wolman disease.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).
Innate Immune, Inc., a privately held biotechnology company, today announced that it has granted to Cephalon Australia Pty Ltd an exclusive license to patents for the development of its antibodies for the treatment of asthma and systemic lupus erythematosis (SLE).
Scientists today described key advances toward practical uses of a new genre of tiny, biocompatible electronic devices that could be implanted into the body to relieve pain or battle infection for a specific period of time, and then dissolve harmlessly.
A unique Network studying the health and wellbeing of older people is bringing together health, social science and mathematics experts in a revolutionary project which will help shape the long-term provision of health and social care services across the UK and ultimately benefit older people.
› Verified 9 days ago
| Entity Name | Yus Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770191900 PECOS PAC ID: 5890115646 Enrollment ID: O20201015001714 |
News Archive
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency, also known as Wolman disease.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).
Innate Immune, Inc., a privately held biotechnology company, today announced that it has granted to Cephalon Australia Pty Ltd an exclusive license to patents for the development of its antibodies for the treatment of asthma and systemic lupus erythematosis (SLE).
Scientists today described key advances toward practical uses of a new genre of tiny, biocompatible electronic devices that could be implanted into the body to relieve pain or battle infection for a specific period of time, and then dissolve harmlessly.
A unique Network studying the health and wellbeing of older people is bringing together health, social science and mathematics experts in a revolutionary project which will help shape the long-term provision of health and social care services across the UK and ultimately benefit older people.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chibong Alex Yu, DO, MPH Po Box 788, Hemet, CA 92546-0788 Ph: (951) 929-6260 | Chibong Alex Yu, DO, MPH 100 S Raymond Ave, Alhambra, CA 91801-3166 Ph: (951) 929-6260 |
News Archive
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency, also known as Wolman disease.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).
Innate Immune, Inc., a privately held biotechnology company, today announced that it has granted to Cephalon Australia Pty Ltd an exclusive license to patents for the development of its antibodies for the treatment of asthma and systemic lupus erythematosis (SLE).
Scientists today described key advances toward practical uses of a new genre of tiny, biocompatible electronic devices that could be implanted into the body to relieve pain or battle infection for a specific period of time, and then dissolve harmlessly.
A unique Network studying the health and wellbeing of older people is bringing together health, social science and mathematics experts in a revolutionary project which will help shape the long-term provision of health and social care services across the UK and ultimately benefit older people.
› Verified 9 days ago
Dr. Nora K Tee, M.D Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 841 W Valley Blvd Ste 107, Alhambra, CA 91803 Phone: 626-282-3657 Fax: 626-282-2759 | |
Dr. Hueyyuan L Wu, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 55 S Raymond Ave, Alhambra, CA 91801 Phone: 626-293-1350 Fax: 626-570-5638 | |
Dr. Kelvin Eric Yeh, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 723 S Garfield Ave Ste 202, Alhambra, CA 91801 Phone: 626-960-2326 Fax: 626-960-9796 | |
Byron Hsieh-lun Lin, M.D. Infectious Disease Medicare: May Accept Medicare Assignments Practice Location: 1153 S. Garfield Ave., Alhambra, CA 91801 Phone: 626-281-1961 | |
Jacqueline C Wong, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1336 W Valley Blvd, Suite A, Alhambra, CA 91803 Phone: 626-281-2232 Fax: 626-281-7214 | |
Inez Cheng, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1108 S Garfield Ave, Alhambra, CA 91801 Phone: 626-975-9027 |